文献速递前列腺癌

基于新型尿液生物标志物风险评分与标准诊疗在前列腺癌诊断中的成本效益:决策分析模型

Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model.
PubMed 文献 · BJU Int · 2017-04-29

本研究采用决策树与马尔可夫模型,在PSA>3 ng/mL男性中比较SelectMDx作为反射检测与仅用PSA选择经直肠超声引导穿刺的标准诊疗的成本效益。结果显示,以高级别前列腺癌灵敏度95.7%为切点的SelectMDx策略较标准诊疗每例节省128欧元并增加0.025质量调整生命年。作者认为,基于现有证据,SelectMDx可能减少过度诊断和过度治疗,从而降低总成本并增加质量调整生命年。

要点

  • 在PSA>3 ng/mL男性中,SelectMDx策略较标准诊疗每例节省128欧元并增加0.025质量调整生命年。
  • 模型时间跨度设定为18年,概率、效用与成本来自文献和专家意见。
  • 敏感性分析显示,主动监测的负效用对质量调整生命年增益影响较大。

核心结论

  • 基于现有证据,在PSA>3 ng/mL男性中使用SelectMDx检测减少过度诊断和过度治疗,可能降低每例患者总成本并增加质量调整生命年。

研究设计与样本

  • 开发决策树与马尔可夫模型,评估SelectMDx作为反射检测与标准诊疗在PSA>3 ng/mL男性中的成本效益。
  • 转移概率、效用与成本来自文献和专家意见,模拟患者18年时间跨度。
  • 进行确定性敏感性分析以处理假设的不确定性。

主要发现

  • 以高级别前列腺癌灵敏度95.7%为切点的SelectMDx诊断策略较标准诊疗策略每例节省128欧元,并增加0.025质量调整生命年。
  • 敏感性分析显示,主动监测的负效用对质量调整生命年增益影响较大,经直肠超声引导穿刺的负效用仅轻微影响模型结果。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the cost-effectiveness of a new urinary biomarker-based risk score (SelectMDx; MDxHealth, Inc., Irvine, CA, USA) to identify patients for transrectal ultrasonography (TRUS)-guided biopsy and to compare this with the current standard of care (SOC), using only prostate-specific antigen (PSA) to select for TRUS-guided biopsy. MATERIALS AND METHODS: A decision tree and Markov model were developed to evaluate the cost-effectiveness of SelectMDx as a reflex test vs SOC in men with a PSA level of >3 ng/mL. Transition probabilities, utilities and costs were derived from the literature and expert opinion. Cost-effectiveness was expressed in quality-adjusted life years (QALYs) and healthcare costs of both diagnostic strategies, simulating the course of patients over a time horizon representing 18 years. Deterministic sensitivity analyses were performed to address uncertainty in assumptions. RESULTS: A diagnostic strategy including SelectMDx with a cut-off chosen at a sensitivity of 95.7% for high-grade prostate cancer resulted in savings of €128 and a gain of 0.025 QALY per patient compared to the SOC strategy. The sensitivity analyses showed that the disutility assigned to active surveillance had a high impact on the QALYs gained and the disutility attributed to TRUS-guided biopsy only slightly influenced the outcome of the model. CONCLUSION: Based on the currently available evidence, the reduction of over diagnosis and overtreatment due to the use of the SelectMDx test in men with PSA levels of >3 ng/mL may lead to a reduction in total costs per patient and a gain in QALYs.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Dijkstra S, Govers TM, Hendriks RJ, et al. Cost-effectiveness of a new urinary biomarker-based risk score compared to standard of care in prostate cancer diagnostics - a decision analytical model. BJU Int. 2017. PMID: 28370948. doi:10.1111/bju.13861

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。